Medigus Ltd. (NASDAQ:MDGS) has announced the news of the first ten MUSE procedures which were carried out in China as part of clinical trials involving the Chinese Food and Drug Administration.
Medigus revealed that the first ten MUSE procedures which were part of the clinical trial which involved 62 patients and were carried out across the country. The aim of the clinical trials is to determine whether or not MUSE will be cleared for sale in China. The procedures are currently ongoing and the findings will be submitted to the CFDA after roughly 12 months of clinical trials.
“The availability of the MUSE™ procedure in China provides patients with a less invasive option for the long-term treatment of GERD,” pointed out the principal investigator, Yunsheng Yang, who also happens to be the Director of Gastroenterology Department Clinical center at 301 Hospital.
Medigus CEO optimistic about the adoption of MUSE in the East Asian market
Medigus Chief Executive Chris Rowland believes that the results of the clinical trials will be as expected. He is optimistic that the clinical trials will be successful and hopes that China will be at the forefront when it comes to adoption of MUSE, especially in the East Asia market. The company expects the country to play a key role towards the adoption of the treatment as well as boosting revenue.
Rowland described the first ten MUSE procedures as a milestone in Medigus’ mission to expand the use of MUSE to a global scale. He pointed out that the availability of the drug in China would offer patients an alternative that would be less invasive as far as gastroesophageal reflux disease (GERD) treatment is concerned. He also noted that the treatment would offer new hope as well as a solution between surgical procedures and drug therapy. The MUSE treatment incorporates a transoral stapler that takes advantage of the latest advances in surgical, ultrasonic and microvisual strapling. This treatment is expected to make it easier to treat GERD. It also aligns with Medigus’ strategy of coming up with highly innovative and minimally invasive endosurgical tools.
Medigus stock closed the latest trading session on Wednesday at $2.56, following a 0.39 percent decline from the value of the stock during the previous close.
